3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮
3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮
![3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮 结构式](https://img.chemicalbook.com/CAS/20180808/GIF/257879-35-9.gif)
3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮 性质
| 溶解度 | DMF：10mg/mL； DMSO：10mg/mL；乙醇：1mg/mL； PBS（pH 7.2）：0.25 mg/mL |
|---|---|
| 形态 | 固体 |
| 颜色 | 黄至橙色 |
3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮 用途与合成方法
|
human PKCβ1 21 nM (IC 50 ) |
human PKCβ2 5 nM (IC 50 ) |
PKCα 331 nM (IC 50 ) |
PKCβ inhibitor 1 (0-30 μM; 48 hours) suppresses tumor cell proliferation in a time- and dose-dependent manner.
PKCβ inhibitor 1 (14 μM; 2-48 hours) induces apoptosis in 2F7 cells.
PKCβ inhibitor 1 (15 μM; 2-48 hours) inhibits cell cycle progression in 2F7 and BCBL-1 cells.
PKCβ (15 or 14 μM, respectively; 2-48 hours) inhibitor 1 reduces the expression of phospho-PKCβ in BCBL-1 and 2F7 cells.
PKCβ inhibitor 1(0-48 hours) suppresses GSK3β, mTOR, and S6 phosphorylation.
Cell Proliferation Assay
| Cell Line: | 2F7, BCBL-1 cells |
| Concentration: | 0, 5, 10, 20, and 30 μM |
| Incubation Time: | 48 hours |
| Result: | A dose-dependent reduction in viability of the 2F7 and BCBL-1 cells starting at 5 μM and increasing with elevated inhibitor concentration. |
Apoptosis Analysis
| Cell Line: | 2F7 cells |
| Concentration: | 14 μM |
| Incubation Time: | 2-48 hours |
| Result: | Apoptotic induction in 2.1% of the 2F7 cells above background after 2 hours of treatment, increasing through 48 hours of treatment. |
Cell Cycle Analysis
| Cell Line: | BCBL-1 Cells |
| Concentration: | 15 μM (the IC 50 ) |
| Incubation Time: | 2-48 hours |
| Result: | Inhibits cell cycle progression in 2F7 and BCBL-1 cells. |
Western Blot Analysis
| Cell Line: | BCBL-1 and 2F7 cell lines |
| Concentration: | 15 or 14 μM (at the IC 50 respectively) |
| Incubation Time: | 2-48 hours |
| Result: | The expression of phospho-PKCβ in BCBL-1 and 2F7 cells reduced. |
3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-13335 | 3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮 | 257879-35-9 | 500μg | 1100 |
| 2024-04-30 | HY-13335 | 3-[1-[3-(1H-咪唑-1-基)丙基]-1H-吲哚-3-基]-4-(苯氨基)-1H-吡咯-2,5-二酮 | 257879-35-9 | 1mg | 1800 |
